<DOC>
	<DOCNO>NCT00002379</DOCNO>
	<brief_summary>To evaluate safety tolerance adefovir dipivoxil indinavir administer orally combination zidovudine , lamivudine , stavudine HIV-infected patient CD4 cell count &gt; = 100 cells/mm3 HIV-1 RNA baseline copy number &gt; = 5000 copies/ml . To determine proportion patient whose plasma HIV-1 RNA level fall level detection ( 500 copies/ml ) 20 week study therapy average reduction HIV-1 RNA baseline study week 20 . To evaluate durability antiviral response 48 week study patient continue study therapy week 24 .</brief_summary>
	<brief_title>The Safety Effectiveness Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine Lamivudine Stavudine HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs</brief_title>
	<detailed_description>This protocol stratify , randomize , open-label study safety efficacy adefovir dipivoxil indinavir quadruple therapy combination zidovudine lamivudine , triple combination administer either zidovudine lamivudine stavudine 48 week treatment HIV-infected patient CD4 cell count &gt; = 100/mm3 HIV-1 RNA baseline copy number &gt; = 5000 copies/ml . Patients randomize adefovir dipivoxil , indinavir , zidovudine , lamivudine adefovir dipivoxil , indinavir , nucleoside inhibitor ( randomly assign receive zidovudine , lamivudine , stavudine ) indinavir , zidovudine , lamivudine . Additionally , daily dose L-carnitine administered patient randomize arm containing adefovir dipivoxil .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Patients must : Laboratory diagnosis HIV infection ( positive HIV antibody test confirm Western blot , p24 antigen assay , HIV1 RNA , HIV1 culture ) . An HIV1 RNA plasma titer &gt; = 5000 copies/ml within 1421 day prior baseline visit . CD4 cell count &gt; = 100 cells/mm3 within 1421 day prior baseline visit . A minimum life expectancy least 1 year . Signed , inform consent parent legal guardian patient &lt; 18 year age . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active , serious infection ( HIV infection ) require parenteral antibiotic antiviral therapy . Patients consider recover infectious episode least 2 week elapse follow cessation parenteral therapy baseline visit . Exhibiting evidence gastrointestinal malabsorption syndrome chronic nausea vomiting may confer inability receive orally administer medication . Malignancy cutaneous Kaposi 's sarcoma ( KS ) basal cell carcinoma . Patients biopsyconfirmed cutaneous KS eligible , must receive systemic therapy KS within 4 week prior baseline anticipated require systemic therapy study . Any clinical condition opinion investigator would make patient unsuitable study unable comply dose requirement . Patients follow prior condition exclude : A new AIDSdefining event diagnose within 1 month prior baseline . Any patient previously discontinue zidovudine , lamivudine , and/or stavudine due drugrelated toxicity . Significant history peripheral neuropathy . 1 . Treatment immunomodulating agent systemic corticosteroid , IL2 , interferon . Saquinavir , ritonavir , nelfinavir , nevirapine , delavirdine , didanosine , dideoxycytidine , interferon alpha , interferon beta , isoniazid , rifampin , investigational agent ( except upon Sponsor approval ) , chemotherapeutic agent ( systemic ) , terfenadine , astemizole , cisapride , triazolam , midazolam . 1 . Prior use adefovir dipivoxil . Prior nonprotease antiretroviral therapy ( antiretroviral vaccine ) great 4 cumulative week . Prior use antiretroviral protease inhibitor . Immunizations within 30 day baseline . Antiretroviral vaccine therapy within 60 day baseline . Treatment 4 week prior baseline , immunomodulating agent systemic corticosteroid , IL2 , interferon . Any investigational drug within 30 day prior baseline . Any prior therapy , opinion investigator , would make patient unsuitable study unable comply dose requirement . Patients current alcohol substance abuse judge investigator potentially interfere patient compliance .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 1998</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Adenine</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>